Kassouf E, et al. ELCC2018, abstract 213_PR.
Adjuvant pembrolizumab versus observatie bij spierinvasief urotheelcarcinoom
feb 2025 | Immuuntherapie, Uro-oncologie
nov 2024 | Longoncologie
nov 2024 | Longoncologie
feb 2024 | Longoncologie
dec 2023 | Uro-oncologie
jun 2021 | Chirurgie, Maag-darm-leveroncologie
feb 2021 | Maag-darm-leveroncologie